Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late (Q42207323)
Jump to navigation
Jump to search
scientific article published on 3 July 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late |
scientific article published on 3 July 2014 |
Statements
1 reference
Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late (English)
1 reference
Stefan Zeuzem
1 reference
Viola Knop
1 reference
Ilaria Lenci
1 reference
Marzia Montalbano
1 reference
Raffaella Lionetti
1 reference
Christine Durand
1 reference
Peter Ferenci
1 reference
Gianpiero D'Offizi
1 reference
Andrea Telese
1 reference
Arnaldo Andreoli
1 reference
3 July 2014
1 reference
1 reference
Identifiers
1 reference